Theseus Pharmaceuticals, Inc. Common Stock
THRX
THRX was delisted on the 13th of February, 2024.
47 hedge funds and large institutions have $403M invested in Theseus Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
2% more funds holding
Funds holding: 46 → 47 (+1)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
9% less capital invested
Capital invested by funds: $441M → $403M (-$38.6M)
20% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$2.17M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.47M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.16M |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$641K |
| 5 |
State Street
Boston,
Massachusetts
|
+$597K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.54M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$562K |
| 3 |
D.E. Shaw & Co
New York
|
-$281K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$272K |
| 5 |
CCM
CAAS Capital Management
New York
|
-$190K |
THRX Hedge Fund Activity: Q1 2022 in Review
47 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q1 2022, worth a combined $403M — down 8.7% from $441M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new THRX positions and 4 closed out — a net gain of 1 holder — while 12 added to existing stakes and 15 trimmed.
The largest buyer was OrbiMed, adding an estimated $2.17M. The largest seller was Wellington Management Group, cutting an estimated $3.54M.
- 47 institutional investors held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q1 2022, up from 46 in Q4 2021.
- Funds reported $403M of Theseus Pharmaceuticals, Inc. Common Stock stock for Q1 2022, down 8.7% quarter-over-quarter.
- 5 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 4 closed out, a net change of +1 holder.
- The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was OrbiMed, an estimated $2.17M added.
- The largest Theseus Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was Wellington Management Group, an estimated $3.54M sold.
Based on aggregated 13F filings for Q1 2022.